Pfizer Corporation

Asher Biotherapeutics, Inc.

Genentech, Inc.

F. Hoffmann-La Roche Ag

Yik Andy Yeung

Javier Fernando Chaparro Riggers

Wei Chen

Arvind Rajpal

Pavel Strop

Thomas John Van Blarcom

Tracy Chia-Chien Kuo

Weihsien Ho

Leila Marie Boustany

Edward Derrick Pascua

Amy Shaw-Ru Chen

Cesar Adolfo Sommer

Danielle Elizabeth Dettling

Ivana Djuretic

Henry C Nguyen

David Y Liu

Henry Bernard Lowman

Kristian Todd Poulsen

Veena Krishnamoorthy

Renee L Greer

Byong Kang

Napoleone Ferrara

Barbra Johnson Sasu

Lidia Mosyak

Laura Lin

Yu-Ju G Meng

Irene Ni

Kelly Dare Moynihan

Reid Martin Renny Feldman

Danielle C Pappas

Ling Hon Matthew Chu

Terrence Park

Paul Bessette

Moustafa Marc Hamze

Sherman Michael Chin

Lisa A Damico

Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).

Chimeric antigen receptors targeting FLT3

The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

IL-21 polypeptides and targeted constructs

The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).

Antibodies specific for FLT3 and their uses

Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.

Fusions with CD8 antigen binding molecules for modulating immune cell function

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Therapeutic antibodies and their uses

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.

IL-15 variants and uses thereof

Growing community of inventors

South San Francisco, CA, United States of America

Yik Andy Yeung